Hims & Hers Health, Inc. (NYSE:HIMS) Receives $32.50 Consensus Price Target from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $32.50.

HIMS has been the subject of a number of research reports. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. TD Cowen raised their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. reduced their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Needham & Company LLC upped their target price on Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 4,938 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the sale, the chief financial officer directly owned 264,117 shares of the company’s stock, valued at approximately $7,920,868.83. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares in the company, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 190,227 shares of company stock valued at $6,133,613 in the last 90 days. Company insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HIMS. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Versant Capital Management Inc grew its holdings in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares during the period. Silicon Valley Capital Partners acquired a new position in Hims & Hers Health in the 3rd quarter valued at about $48,000. Finally, EverSource Wealth Advisors LLC raised its stake in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
• Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
• Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
• Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $27.66 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $65.30. The firm’s 50 day moving average is $31.67 and its two-hundred day moving average is $26.75. The firm has a market capitalization of $6.45 billion, a P/E ratio of -43.90 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the firm posted $0.17 EPS. The firm’s quarterly revenue was up 38.2% compared to the same quarter last year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.